Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,943 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
Ehlers JP, Uchida A, Hu M, Figueiredo N, Kaiser PK, Heier JS, Brown DM, Boyer DS, Do DV, Gibson A, Saroj N, Srivastava SK. Ehlers JP, et al. Among authors: gibson a. Ophthalmol Retina. 2019 Dec;3(12):1056-1066. doi: 10.1016/j.oret.2019.06.010. Epub 2019 Jul 6. Ophthalmol Retina. 2019. PMID: 31473172 Free PMC article. Clinical Trial.
Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials.
Wykoff CC, Marcus DM, Midena E, Korobelnik JF, Saroj N, Gibson A, Vitti R, Berliner AJ, Williams Liu Z, Zeitz O, Metzig C, Schmelter T, Heier JS. Wykoff CC, et al. Among authors: gibson a. JAMA Ophthalmol. 2017 Feb 1;135(2):107-114. doi: 10.1001/jamaophthalmol.2016.4912. JAMA Ophthalmol. 2017. PMID: 28006063
Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.
Hernandez L, Lanitis T, Cele C, Toro-Diaz H, Gibson A, Kuznik A. Hernandez L, et al. Among authors: gibson a. J Manag Care Spec Pharm. 2018 Jul;24(7):608-616. doi: 10.18553/jmcp.2018.24.7.608. J Manag Care Spec Pharm. 2018. PMID: 29952707 Free PMC article.
Given the similar efficacy and safety profiles between IAI and ranibizumab, their associated costs and comparative cost-effectiveness are key factors in determining which one represents a more rational investment of scarce health care resources to help address the increasi …
Given the similar efficacy and safety profiles between IAI and ranibizumab, their associated costs and comparative cost-effectiveness are ke …
Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.
Khurana RN, Rahimy E, Joseph WA, Saroj N, Gibson A, Vitti R, Berliner AJ, Chu K, Cheng Y, Boyer DS. Khurana RN, et al. Among authors: gibson a. Am J Ophthalmol. 2019 Apr;200:161-168. doi: 10.1016/j.ajo.2019.01.005. Epub 2019 Jan 19. Am J Ophthalmol. 2019. PMID: 30664844 Clinical Trial.
1,943 results